Pradaxa’s U.S. Label Updated To Cite Clinical Superiority To Warfarin In Stroke Prevention

Update of label not based on new post-NDA or post-marketing data, but on a fuller review of pivotal trial data and discussions between Boehringer Ingelheim and FDA.